Heparin-induced thrombocytopenia cost-effectiveness of therapy
|
Heparin-induced thrombocytopenia |
|
Differentiating Heparin-induced thrombocytopenia from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Heparin-induced thrombocytopenia cost-effectiveness of therapy On the Web |
|
American Roentgen Ray Society Images of Heparin-induced thrombocytopenia cost-effectiveness of therapy |
|
FDA on Heparin-induced thrombocytopenia cost-effectiveness of therapy |
|
CDC on Heparin-induced thrombocytopenia cost-effectiveness of therapy |
|
Heparin-induced thrombocytopenia cost-effectiveness of therapy in the news |
|
Blogs on Heparin-induced thrombocytopenia cost-effectiveness of therapy |
|
Directions to Hospitals Treating Heparin-induced thrombocytopenia |
|
Risk calculators and risk factors for Heparin-induced thrombocytopenia cost-effectiveness of therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [2], Aric C. Hall, M.D., [3], Shyam Patel [4]
Overview
Cost-effectiveness is an important consideration when treating HIT. This is because alternative anticoagulants (other than heparin) can be quite expensive given their unique mechanisms of action and the costs of drug development. It has been shown that fondaparinux is the most cost-effective treatment for HIT, compared to direct thrombin inhibitors.
Cost-Effectiveness of Therapy
There has been one cost-effective analysis of anticoagulants for HIT. The treatment of HIT involves use of alternative anticoagulants, such as direct thrombin inhibitors. However, there is also data for use of the factor X inhibitor fondaparinux, which is less expensive than direct thrombin inhibitors.[1] Fondaparinux would found to be the most cost-effective agent for treatment of HIT, compared to argatroban or bivalirudin. [1]
| Argatroban | Bivalirudin | Fondaparinux | |
|---|---|---|---|
| Cost of administration | $411.43 | $411.43 | $25.40 |
| Average wholesale price | $1194.65 (1 vial of 250mg) | $753.07 (1 vial of 250mg) | $220.34 (1 syringe of 7.5mg) |
| Total cost for 9 days of therapy | $1326 | $1562 | $164 |
As novel anticoagulants become FDA-approved and arrive to the market, cost-effective analysis will need to be considered. Note that newer generation medications typically have higher costs than traditional medications.
References
- ↑ 1.0 1.1 Aljabri A, Huckleberry Y, Karnes JH, Gharaibeh M, Kutbi HI, Raz Y; et al. (2016). "Cost-effectiveness of anticoagulants for suspected heparin-induced thrombocytopenia in the United States". Blood. 128 (26): 3043–3051. doi:10.1182/blood-2016-07-728030. PMID PMID27793877 Check
|pmid=value (help).